A new oral option for people already stable on treatment
The U.S. Food and Drug Administration has approved Merck’s Idvynso, a once-daily tablet that combines doravirine and islatravir for the treatment of HIV-1 infection in adults who are already virologically suppressed. The decision adds a new switch option for patients whose virus is controlled on an existing regimen and who do not have a history of treatment failure or known resistance linked to doravirine.
Idvynso is notable because it packages two antiretroviral agents into a single daily tablet while avoiding tenofovir and integrase inhibitors. In practice, that gives clinicians another way to manage long-term HIV care for patients whose needs may change over time, whether because of tolerability, drug interactions, or a desire to simplify therapy without losing viral control.
Who the approval covers
The label described in the source material is targeted rather than broad. The tablet is intended for adults on a stable antiretroviral regimen whose HIV-1 RNA is below 50 copies per milliliter. It is not framed as a first-line treatment for everyone newly diagnosed with HIV, nor as a rescue therapy for people with known resistance issues.
The fixed-dose combination contains 100 milligrams of doravirine and 0.25 milligrams of islatravir. According to the supplied source text, the product is contraindicated with strong cytochrome P450 3A inducers as well as lamivudine or emtricitabine. Those restrictions matter because HIV treatment decisions often turn on the details of a patient’s broader medication list and prior treatment history.
